Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, talks on the use of the potentially disease-modifying bromodomain inhibitor, pelabresib, for the treatment of myelofibrosis. Dr Bose sheds light on the ongoing MANIFEST (NCT02158858) and MANIFEST-2 (NCT04603495) trials, in which the combination of pelabresib and the JAK inhibitor ruxolitinib are currently under investigation, as well as commenting on the use of pelabresib in different settings. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.